Curis Inc
NASDAQ: CRIS · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-11-12
Curis Inc (CRIS) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for CRIS.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
CRIS historical valuation range
Where current P/E sits in CRIS's own 5Y range.
CRIS intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
CRIS valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 0.46x
P/S Ratio — History
Current: 0.34x
Is CRIS overvalued in 2026?
Curis Inc (CRIS) currently trades at $0.57 per share with a market capitalization of $1,455,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 34/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 0.5x, above its 5-year median of 0.4x.
Looking at its own history, CRIS is currently trading more expensive than 71% of the last 5Y on P/E. This places it in the 71th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates CRIS's intrinsic value at $5.44 per share, against the current market price of $0.57. This implies a margin of safety of +80.51%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: CRIS appears richly valued on our framework, with a Smart Value Score of 34/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is CRIS overvalued?
CRIS scores 34/100 on our Smart Value Score (Grade F), a weak overall profile. The DCF also shows a positive margin of safety, so price and fundamentals line up reasonably well.
What is CRIS's fair value?
Our DCF model estimates CRIS's intrinsic value at $5.44 per share, versus the current price of $0.57, a margin of safety of +80.51%. Fair value is the present value of the cash flows we project the business to produce, so a price below it means the market is pricing the stock below that conservative estimate.
What P/E ratio does CRIS trade at?
CRIS trades at a P/E of 0.5x on trailing twelve-month earnings, against a 5-year median of 0.4x. P/E is what you pay per dollar of profit, and sitting above its own median means the stock is pricier than usual relative to its earnings.
Is CRIS a buy based on valuation?
Our Smart Value rating for CRIS is Strong Sell, from a Smart Value Score of 34/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.
How does CRIS's valuation compare to its history?
On P/E, CRIS sits in the 71st percentile of its own 5Y range, above its long-run median relative to where it has traded. A high percentile means today's multiple is near the top of its historical band.
What is CRIS's Smart Value Score?
CRIS's Smart Value Score is 34/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.